1. Kodani received remuneration from Daiichi-Sankyo and Ono Pharmaceutical; Dr. Inoue received remuneration from Boehringer Ingelheim;Bristol-Myers Squibb;Yamashita received research funding from Bayer Healthcare, Bristol-Meyers Squibb, and Daiichi-Sankyo and remuneration from Bayer Healthcare, Bristol-Myers Squibb, Daiichi-Sankyo, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, and Toa Eiyo,1991
2. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study;T J Wang;Circulation,2003
3. Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society;V Fuster;Circulation,2006
4. Lenient versus strict rate control in patients with atrial fibrillation;I C Van Gelder;N Engl J Med,2010
5. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC;G Hindricks;Eur Heart J,2020